Technology evaluation: edrecolomab, Centocor Inc.

Abstract

Specific targeting of tumor cells may be achieved by using monoclonal antibodies to tumor antigens. Edrecolomab is a mouse-derived monoclonal IGg2A antibody directed against the human tumor-associated CO17-1A (or Ep-CAM) antigen, and is the first monoclonal antibody approved for cancer therapy. Encouraging results of several clinical trials were recently reported using edrecolomab for adjuvant therapy after surgery of Duke's C colorectal cancer. Side effects and toxicity profiles compare favorably to conventional regimens of radio- or chemotherapy. Future challenges lie in further improvement of these novel therapeutics, hopefully generating benefit for a larger number of cancer patients.

• Authors: A Abicht, H Lochmüller
• Journal: Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 2 Issue 5 Pg. 593-600 (Oct 2000) ISSN: 1464-8431 [Print] England
• PMID: 11249762 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Neoplasm
• Antigens, Neoplasm
• Recombinant Proteins
• carcinoma-associated antigen 17-1A
• Interferon-gamma

Topics

• Animals
• Antibodies, Monoclonal (adverse effects, metabolism, therapeutic use)
• Antibodies, Neoplasm (adverse effects, metabolism, therapeutic use)
• Antigens, Neoplasm
• Biotechnology
• Colorectal Neoplasms (therapy)
• Combined Modality Therapy
• Humans
• Immunotherapy (adverse effects, methods)
• Interferon-gamma (therapeutic use)
• Mice
• Neoplasms (drug therapy, immunology, therapy)
• Recombinant Proteins